An observational study in Prostatic Neoplasms, sponsored by Sanofi. Terminated at 5 sites in 5 countries. Open to male participants. Per ClinicalTrials.gov, last updated 2011-02-14.
Sponsored by Sanofi · Observational
Primary Objective:
Secondary Objective:
6,484 studies on the registry are indexed under Prostatic Neoplasms; 1,415 are open to participants now.
This study's enrollment of 82 is below the median of 200 across 1,200 observational studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Sanofi is the lead sponsor of 1,547 studies on the registry; 88 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 122 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with metastatic castrate-resistant prostate cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Overall survival
Time frame: At Month 12 or death
Sequence of treatment in second-line, third-line
Time frame: At Month 6 (+/- 2 months), Month 12 or death
Characteristics and outcomes of patients who receive second-line taxane-based treatment compared to others
Time frame: At baseline, Month 6 (+/- 2 months), Month 12 or death
Indicators of health care resource utilization
Time frame: At baseline, Month 6 (+/- 2 months), Month 12 or death
Quality of life
Time frame: At baseline, Month 6 (+/- 2 months) or Month 12
This study is terminated, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.